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Abstract: The proteasome inhibitor MLN9708 is an orally administered drug that is hydrolyzed into its active form, 
MLN2238 (ixazomib). Compared with Bortezomib, MLN2238 has a shorter proteasome dissociation half-life and a 
lower incidence and severity of peripheral neuropathy, which makes it an attractive candidate for colorectal cancer 
treatment. In the present study, we observed that MLN2238 induced autophagy, as evidenced by conversion of the 
autophagosomal marker LC3 from LC3I to LC3II, in colorectal cancer cell lines. Mcl-1, an anti-apoptotic Bcl-2 family 
protein, was markedly elevated after treating a colorectal cancer cell line with MLN2238. We proved that inhibiting 
Mcl-1 expression enhances MLN2238 induced apoptosis and negatively regulates autophagy. Co-administration of 
BH3 mimetic ABT-737 with MLN2238 synergistically kills colorectal cancer cells through MCL-1 neutralization and 
autophagy inhibition. Furthermore, the synergistic killing effect of the combination therapy is correlated with P53 
status in colorectal cancer. These data highlight that the combination of ABT-737 with MLN9708 is a promising 
therapeutic strategy for human colorectal cancer.
Keywords: Colorectal cancer, MLN9708, ABT-737, autophagy, MCL-1 
Introduction
The latest cancer statistics according to 
GLOBOCAN reveal that colorectal cancer is the 
third most commonly diagnosed cancer in 
males and the second most common in fe- 
males, with over 1.3 million new cancer cases 
and nearly 700,000 deaths in 2012 [1]. Despite 
the introduction of several new drugs for the 
treatment of colorectal cancer over the last 
decade that have prolonged survival of ad- 
vanced stage patients, the disease remains 
lethal and new treatments with milder side-
effects are urgently needed. 
Proteasome inhibitors have been shown to 
inhibit proliferation and induce apoptosis in a 
variety of cell types. Hematologic cancer de- 
rived cells are among the most sensitive to pro-
teasome inhibition [2]. However, the efficacy of 
proteasome inhibitors as single agent using in 
vitro and in vivo colorectal cancer models is lim-
ited and often requires high doses [3, 4]. These 
drugs also do not show obvious activity in 
patients with metastatic colorectal cancer in 
clinical trials [5]. Autophagy has been reported 
as a mechanism of drug resistance that may 
reverse or retard therapeutic efficiency [6, 7]. 
Autophagy is known as a catabolic process that 
targets cellular organelles and cytoplasmic con-
stituents to the lysosomes for degradation [8]. 
The role of autophagy in colorectal cancer and 
other cancers remains controversial, it can 
cause both cell death and survival [9-11]. 
Several anticancer drugs have been shown to 
induce autophagy as well as apoptosis [12]. 
Proteasome inhibitors can induce ER stress in 
cancer cells [13] and ER stress response is 
known to be involved in both apoptosis and 
autophagy [14, 15]. Autophagy appears to be 
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up regulated in colorectal cancer and generally 
associated with poor prognosis and drug resis-
tance [16]. Experimental studies have indicat-
ed that in the case of colorectal cancer cell 
lines that were resistant to nutrient deprivation 
culture conditions, autophagy might provide an 
alternative source of energy through degrada-
tion of its organelles [17]. Inhibition of auto- 
phagy substantially increased apoptosis and 
significantly attenuated senescence in colorec-
tal cancer cells by blocking p53/p21 pathway 
[18]. The inhibition also reduced cancer stem-
like cell tumorigenicity in vivo [19]. Recent stud-
ies also suggest that autophagy inhibitors given 
in combination with pro-apoptotic agents may 
enhance chemosensitization in human cancer 
cells [20].
In the present study, we investigated the effec-
tiveness of combining BH3 mimetic, ABT-737, 
with proteasome inhibitor, MLN2238 (ixazo-
mib), on colorectal cancer cell lines in vitro. We 
observed that sensitivity of colorectal cancer 
cell lines to proteasome inhibition was autoph-
agy-related. In addition, we found that BCL-2 
family proteins were involved in the protea-
some inhibitor efficacy. In this study, we show 
that the combination of the two drugs synergis-
tically kill colon cancer cells. Further, we found 
that autophagy induced by MLN2238 can be 
negatively regulated by the BH3 mimetic ABT-
737. Mechanistic analysis suggests that this 
combination increases cell apoptosis and cell 
necrosis by negatively regulating Mcl-1. There- 
fore, combination treatment with MLN2238 
and ABT-737 down regulates autophagy by 
reducing Mcl-1 expression and offers an attrac-
tive strategy to enhance the antitumor efficacy 
of MLN2238.
Materials and methods
Cells and cell culture
Human colon cancer cell lines HT29, LOVO, 
SW480, and HCT116 were purchased from the 
American Type Culture Collection (Manassas, 
VA) and were authenticated by STR assay two 
months before experiments. RKO and HCT116 
P53-/- cell lines were kindly provided by Dr. Eric 
Wickstrom at Thomas Jefferson University (Ph- 
iladelphia, PA). HCT116 Mcl-1 overexpression 
cell line was generated following the protocol 
as reported previously [50]. MC38 cell line was 
kindly provided by Dr. Scott Waldman at Thomas 
Jefferson University (Philadelphia, PA). The 
cells were maintained in RPMI 1640 or EMEM 
or DMEM supplemented with 10% (v/v) fetal 
bovine serum (Invitrogen, Carlsbad, CA, USA). 
All cells were cultured at 37°C in a humidified 
incubator containing 5% CO2.
Chemicals
Ixazomib was provided by Millennium Phar- 
maceuticals (Cambridge, MA, USA) and ABT-
737 were purchased from selleckchem (Hou- 
ston, TX, USA). Inhibitors were diluted in DMSO 
at stock concentrations of 10 and 20 mM 
for in vitro use, respectively. DMSO was pur-
chased from Sigma (St Louis, MO, USA). Mcl-1 
siRNA smart-pool and non-targeting siRNA 
control were purchased from Dharmacon. The 
transfection of siRNA was performed using 
Lipofectamine® RNAiMAX (Invitrogen, Carls- 
bad, CA, USA) according to the manufacturer’s 
instructions. Cells were then cultured for a 48 h 
recovery period before being collected or treat-
ed as indicated.
Cell viability assay
MTS assays were performed using tetrazolium 
based CellTiter 96® AQueous One Solution Cell 
Proliferation assay (Promega; Fitchburg, WI). 
HCT116, RKO, SW480, LOVO and HT-29 cells 
were seeded in 96 well plates at 3,000 cells/
well. Cells were treated with various concentra-
tions of MLN2238 and/or ABT737 one day 
after plating. MTS assay was performed at 24 h 
after treatment with MLN2238 and/or ABT737.
Calculation of combination index
The effect of combination between MLN2238 
and ABT-737 at a fixed ratio (1:10) was ana-
lyzed using Calcusyn software (Biosoft). Deter- 
mination of synergy or antagonism was quan- 
tified by the combination index (CI). CI=1 in- 
dicates an additive effect; < 1, synergy; > 1, 
antagonism.
Flow cytometry assay
Apoptosis was detected using an FITC Annexin-V 
Apoptosis Detection Kit (BD Pharmingen, San 
Diego, CA, USA) according to the manufactur-
er’s instructions. Cells were seeded in 60-mm 
culture plates for a final population of 70% con-
fluence. After treatments, cells were collected 
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with 0.15% trypsin at the indicated times, pel-
leted and washed twice with ice-cold PBS. Cells 
were resuspended in binding buffer (1 × 106 
cells/ml). Then 100 μl of the cell suspension (1 
× 105 cells) was incubated with 5 μl of Annexin-V 
FITC and 5 μl of propidium iodide (PI) for 15 min 
at room temperature in the dark. The popula-
tion of apoptosis cells was analyzed using an 
LSR-II flow cytometer (BD FACSCalibur, Becton 
Dickinson, San Jose, CA, USA).
Western blot analysis
Cells were washed twice with ice-cold PBS and 
then lysed in M-Per mammalian lysis buffer 
(Thermo Scientific; Waltham, MA) plus protease 
and phosphatase inhibitors (2 μg/ml leupeptin, 
2 μg/ml aprotinin, 1 mM PMSF and 0.1 mM 
Na3VO4). The protein concentration of the 
lysates was determined with the Bradford 
reagent (Bio Rad; Hercules, CA) and equal 
amounts of protein were subjected to SDS-
PAGE on a 10% or 15% gel. Separated proteins 
were transferred to a nitrocellulose membrane, 
which was then exposed to 5% non-fat dried 
milk in TBS containing 0.1% Tween 20 (0.1% 
TBST) for 1 h at room temperature and incu-
bated overnight at 4°C with antibodies against 
Mcl-1, LC-3, Atg5, P62, phospho-S6 (p-S6), 
phospho-ERK (p-ERK), Bcl-2, Bcl-xl, Bim (Cell 
Signaling Technology; Danvers, MA), Beclin-1, 
Noxa, PARP, total S-6 (T-S6), total ERK (T-ERK) 
(Santa Cruz Biotechnology; Santa Cruz, CA), 
actin (Sigma-Aldrich; St. Louis, MO). The mem-
branes were then washed with 0.1% TBST 
before incubation with horseradish peroxidase-
conjugated goat antibodies to rabbit or mouse 
(Santa Cruz Biotechnology). Immune complex-
es were detected with chemiluminescence re- 
agents (Pierce ECL Substrate; Thermo Sci- 
entific). The gels were then quantitatively ana-
lyzed comparing the expression levels of the 
Figure 1. ABT-737 sensitizes colorectal cancer cells to MLN2238. Cultured HCT116, LOVO, SW480, HT-29 human 
colorectal cancer cell lines were incubated with (A) MLN2238 or (B) ABT-737 for 24 h at indicated doses. (C) Cell 
lines were treated with MLN2238 (200 nM) and ABT-737 (2 μM). Cell viability was determined using the MTS reduc-
tion assay. Experiments were conducted in triplicate. Mean ± SD. *, P < 0.005, relative to DMSO. (D) Cell lines were 
treated with MLN2238 and ABT-737 at a fixed ratio (1:10), cell viability was measured, and the CI was calculated. 
Isobologram showing CI < 1 indicates synergy. 
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experimental group with a control of actin. 
Images show a representative experiment out 
of 3 with nearly identical results.
In vivo studies 
Animal experiments were approved by Ex- 
perimental Animal Ethics Committee of Fudan 
University Shanghai medical college. A total of 
5 × 105 MC38 murine colorectal cancer cells 
were inoculated subcutaneously in the right 
flank of female C57BL/6 mice (6 weeks old) 
using Matrigel (BD, diluted to 4 mg/ml in PBS). 
Tumors were measured every other day, volume 
was calculated with the formula ([length] × 
[width]2)/2. When the tumors reached a volume 
of ~100 mm3, Mice were randomly assigned 
into four groups receiving: vehicle, MLN2238, 
Figure 2. MLN2238 increases cell apoptosis after ABT-737 co-treatment. Cell lines were treated with MLN2238 
(200 nM), ABT737 (2 μM) or the combination for 24 h. A. Flow cytometry analysis of annexin-V and propidium iodide 
(PI) staining of apoptotic cells following treatment. B. Quantitation of flow cytometry (n=5/group). Mean ± SD. *, P 
< 0.005, relative to MLN2238.
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ABT-737 and combo drugs. MLN2238 was pre-
pared in a 5% solution of 2-hydroxypropyl-β-
cyclodextrin (Sigma-Aldrich). Mice were inject-
ed intraperitoneally with 30 mg/kg of ABT-737 
formulated daily (in 2.5% DMSO, 62.5% H2O 
containing 5% dextrose, 5% Tween-80, 30% 
propylene glycol, final pH 4.5) everyday, or 
MLN2238 (11 mg/kg, i.v) twice weekly for 3 
weeks and both. Animals were euthanized 
when their tumors reached 2 cm3.
Statistical analyses
The values shown represent the mean ± SD for 
triplicate experiments. The statistical signifi-
cance of the differences between experimental 
variables was determined using the Student’s t 
test. P < 0.05 was considered statistically sig-
nificant. Student’s t test and linear regression 
were performed using Excel (Microsoft) and 
Graphpad Prism (Graphpad Software Inc.)
Results
ABT-737 sensitizes colorectal cancer cells to 
MLN2238 
To assess whether ABT-737 could augment the 
efficacy of the MLN2238, we initially treated 
colorectal cancer cell lines (HCT116, LOVO, 
SW480 and HT29) with MLN2238, ABT-737 or 
the combination of both agents. Quantitative 
assessment of viable cells was performed at 
24 hours using a standard MTS assay. In all cell 
lines, MLN2238 (200-500 nM) alone produced 
a modest reduction in cell viability, however, as 
dose increased the efficacy had no obvious 
improvement (Figure 1A). Since ABT-737 (2 μM) 
alone did not have cytotoxicity in these cells 
(Figure 1B), we co-administrated MLN2238 
(200 nM) with ABT-737 (2 μM). This combina-
tion reduced cell viability to a greater extent 
than MLN2238 alone (Figure 1C). We also 
noticed that not all four cell lines responded 
the same to the combination treatment. In 
HCT116 and LOVO, the combination of MLN- 
2238 with ABT-737 significantly decreased 
cell viability (Figure 1C *p < 0.005), while in 
SW480 and HT29, the combination showed 
less efficacy. 
To determine whether the cytotoxic effect of 
the drug combination was synergistic, we per-
formed an analysis with the combination index 
(CI). The cell lines were treated with different 
concentrations of MLN2238 and ABT-737 at a 
fixed ratio (1:10) and cell viability was deter-
mined. The CI value was then calculated using 
Calcusyn software. As shown in the isobolo-
gram, the CI values also showed differences 
between cell lines. A synergistic killing effect 
was observed in HCT116 and LOVO, but not in 
SW480 and HT29 (Figure 1D). 
MLN2238 induces significant apoptosis after 
ABT-737 co-treatment
MTS data showed that MLN2238 and ABT-737 
combination treatments displayed strong syn-
ergistic killing effects for HCT116 and LOVO 
cells. We thus investigated the type of cell 
death induced by treatment of colon cancer 
cells with MLN2238 alone or in combination 
with ABT-737. Utilization of propidium iodide 
(PI) and fluorescein isothiocyanate (FITC)-con- 
jugated Annexin V (Annexin V-FITC) is a stan-
dard procedure to monitor the progression of 
apoptosis. Early apoptotic cells are Annexin 
V-positive and PI-negative (Annexin V+/PI−), 
whereas late apoptotic cells are Annexin V/PI 
double positive (Annexin V+/PI+) [21]. The 
results of Annexin V/PI staining showed a mini-
mal cell death rate was detected when exposed 
to MLN2238 alone (approximately 10-15% cell 
death in HCT116 and LOVO). When cells were 
co-treated with MLN2238 and ABT-737, there 
was a significant increase in death rate (up to 
45-50% in HCT116, nearly 60% in LOVO) (Figure 
2A). There was a noticeable increase of early 
apoptotic cell in HCT116 and LOVO after combo 
treatment, but not in SW480 and HT29. The 
findings were similar to the MTS results. ABT-
737 significantly enhanced MLN2238 induced 
cell death in HCT116 and LOVO (Figure 2B 
MLN2238 vs COMBO, P < 0.005), while no sig-
nificantly increased cell death was observed in 
SW480 and HT-29 (Figure 2B MLN2238 vs 
COMBO, P > 0.1). Since the efficacy difference 
between cell lines may be related to different 
gene status, we compared the results with 
genomic features of these cancer cell lines and 
found the synergistic effect may be related to 
differing p53 status (HCT116 and LOVO, p53 
wild-type; SW480 and HT29, p53 mutant type). 
MLN2238 induced autophagy is inhibited by 
ABT-737 with degradation of the anti-apoptotic 
protein Mcl-1
Several anticancer drugs have been shown to 
induce both apoptosis and autophagy [16]. We 
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explored whether MLN2238 can induce au- 
tophagy, by detecting expression of the light 
chain 3 (LC3) protein that is associated with 
autophagosomal membranes [22]. We found 
MLN2238 can induce autophagy in colon can-
cer cell lines HCT116, LOVO, SW480, HT-29 
with the conversion of cytoplasmic LC3I to 
membrane-bound LC3II as detected by immu-
noblotting. This conversion can be inhibited by 
co-administering the BH3 mimetic ABT-737 in 
cell lines HCT116 and LOVO but not in cell lines 
HT-29 or SW480. We also observed decreased 
Beclin-1 when treated with both drugs in cell 
lines HCT116 and LOVO, but not in cell lines 
HT-29 or SW480, and there is no change in 
ATG5 in these cell lines (Figure 3). Additionally, 
MLN2238-induced cleavage of poly (ADP-ri- 
bose) polymerase (PARP) was dramatically en- 
hanced in HCT116 and LOVO cells after ABT-
737 treatment. Interestingly, RKO cells did not 
show a reduction of LC3I to LC3II conversion 
induced by MLN2238 in the combination group, 
but cleavage of PARP still increased. This result 
was in accord with Annexin V/PI staining data 
(Figure S1). It has been reported that Bcl-2 neg-
atively regulates proteasome induced cell de- 
ath and contributes to the proteasome resis-
tance [23]. By checking Bcl-2 family protein sta-
tus in these colon cancer cell lines, we demon-
strated that Mcl-1, but not Bcl-XL or Bcl-2, accu-
mulation was found in all of these cell lines 
after MLN2238 treatment. In subsequent ex- 
periments we examined whether the accumula-
tion of Mcl-1 induced by MLN2238 in human 
colon cancer lines can be inhibited by co-
administration of the BH3 mimetic ABT-737. 
MLN2238 and ABT-737 synergy is altered by 
regulation of Mcl-1 expression
In HCT116 and LOVO cells, we observed a sig-
nificant reduction in Mcl-1 expression in the 
combination treatment group along with a con-
comitant decrease in LC3II. To determine the 
connection between the Mcl-1 and LC3II de- 
crease, we overexpressed Mcl-1 in the HCT116 
cell line and treated with drugs as described 
above. We found that in the combination group 
Mcl-1 decreased slightly but the conversion of 
LC3I to LC3II was not blocked by the co-treat-
ment (Figure 4A). Annexin V/PI staining proved 
Mcl-1 overexpression in the HCT116 cell line 
did not show a synergistic effect in the combi-
nation treatment (Figure 4C, 4D MLN2238 vs 
COMBO, P > 0.1). Interestingly, Mcl-1 does not 
appear to be a direct activator of autophagy. 
Overexpression of Mcl-1 does not increase 
baseline or MLN2238 induced autophagy in 
Figure 3. MLN2238 induced autophagy is inhibited by ABT-737 with degradation of the anti-apoptotic protein Mcl-1. 
Cell lines were treated with doses of MLN2238 (200 nM), ABT737 (2 μM),or the combination for 24 h.Protein lysates 
were harvested and western blots performed using antibodies for Mcl-1, LC3, Beclin1, Atg5, Bcl-xl, Bcl2, PARP and 
Actin.
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HCT116 (Figure 4A). When HCT116 cells were 
treated with MLN2238 and Mcl-1 siRNA, we 
found an increased killing effect in the Mcl-1 
knockdown group, accompanied with decre- 
ased LC3II (Figure 4B). Taken together, our 
data suggest that the combination of MLN22-
38 with BH3 mimetic ABT-737 enhances the 
MLN2238 killing effect by decreasing the Mcl-1 
expression and blocks autophagy by reducing 
the conversion of LC3I to LC3II.
P53 related synergistic effect and LC3 expres-
sion
In order to further explore whether or not 
MLN2238 and ABT-737 synergism is related to 
P53 status in the cell lines, we treated HCT-116 
P53-/- cells with drugs as indicated previously. 
Annexin V/PI staining of HCT116 P53-/- cells 
not only showed no synergy between MLN2238 
and ABT-737, but HCT116 P53-/- cells also 
appear resistant to these two drugs individually 
(Figure 5A, 5B MLN2238 vs COMBO, P > 0.1). 
Western-blot showed the conversion of LC3I to 
LC3II could not be inhibited by co-administra-
tion of ABT-737 in HCT116 P53-/- cells (Figure 
5C). We showed HCT116 P53-/- cells are resis-
tant to the combination treatment with high 
expression of Mcl-1 and LC3II. This result 
shows that the sensitivity of colon cancer cell 
lines to combination therapy is correlated with 
P53 status. 
Combination of MLN2238 and ABT-737 in-
hibits tumor growth in colon cancer allograft 
model
To test whether the combined effects of 
MLN2238 and ABT-737 observed in vitro would 
translate to an in vivo model, we examined 
effects of MLN2238 or ABT-737 and combo 
group in MC38 mouse allografts. In our in vivo 
Figure 4. MLN2238 and ABT-737 synergy is altered by regulation of Mcl-1 expression. A. HCT116 cells overexpress-
ing Mcl-1 were treated with doses of MLN2238 (200 nM), ABT737 (2 μM) or the combination for 24 h. Protein 
lysates were harvested and western blots performed using antibodies for Mcl-1 and LC3. B. Mcl-1 siRNA treated 
HCT116 cells were given dose of MLN2238 (200 nM). Protein lysates were harvested and Mcl-1 and LC3 levels were 
detected by western blots. C. HCT116 Mcl-1 overexpression cells were treated with doses of MLN2238 (200 nM), 
ABT737 (2 μM), or the combination for 24 h. Flow cytometry analysis of annexin-V and propidium iodide (PI) staining 
of apoptotic cells following the treatment. D. Quantitation of flow cytometry (n=5/group). Mean ± SD. 
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Figure 5. Synergistic effect of MLN2238 and ABT 737 is P53 re-
lated. HCT116 P53-/- cells were treated with doses of MLN2238 
(200 nM), ABT737 (2 μM), or the combination for 24 h. A. Flow 
cytometry analysis of annexin-V and propidium iodide (PI) stain-
ing of apoptotic cells following the treatment. B. Quantitation 
of flow cytometry (n=5/group). Mean ± SD. C. Protein lysates 
were harvested and western blots performed using antibodies 
for Mcl-1, LC3, Beclin1, Atg5, Bcl-xL, Bcl2, PARP and Actin.
Figure 6. Combination of MLN2238 and ABT-737 inhibits tumor growth in colon cancer allograft model. A total of 
5 × 105 MC38 murine colorectal cancer cells were inoculated subcutaneously in the right flank of female C57BL/6 
mice. A. Representative tumor growth in mice treated with vehicle, MLN2238, ABT-737 and combo drugs. B. Tumor 
volume was calculated from day 8 to day 24 (n=6/group). Mean ± SD. *, P < 0.05. C. The average weight of the mice 
was monitored after treatments. 
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model, MLN2238 alone inhibited tumor growth 
compared to control, but ABT-737 alone showed 
no potent alone in inhibiting tumor growth. 
Combination of MLN2238 and ABT-737 pro-
duced greater inhibition of tumor growth than 
either agent did alone (Figure 6A, 6B). Mice 
body weights were monitored to assess the tol-
erability of combination therapy (Figure 6C). 
Body weight changes over the course of the 
experiment were minimal in all treatment 
groups, suggesting that combined MLN2238 
with ABT-737 is well tolerated. These results 
provided a rationale for combined MLN2238 
and ABT-737 therapy as a strategy to inhibit 
tumor growth in vivo.
Discussion
Colorectal cancer is the second leading cause 
of cancer related mortality in the United States 
[24]. Despite the introduction of several new 
drugs for colorectal cancer treatment over the 
last decade, the disease remains lethal and 
new treatments with less off target toxicities 
are urgently needed. Proteasome inhibitors 
have documented efficacy in a number of 
hematologic malignancies, especially in multi-
ple myeloma and mantle cell lymphoma [25, 
26]. However, proteasome inhibitor studies in 
solid tumors have yielded disappointing results 
[27-29]. Bortezomib’s toxicity, especially Bor- 
tezomib induced peripheral neuropathy (BIPN), 
may be a major obstacle in the clinical develop-
ment of BTZ chemotherapy-based regimens in 
solid tumors. Therefore, it is imperative that a 
new generation proteasome inhibitors be devel-
oped with better therapeutic efficacy and fewer 
side effects.
MLN9708 (ixazomib citrate) is an orally admin-
istered drug that is hydrolyzed into its active 
form, MLN2238 (ixazomib). Compared with 
BTZ, MLN2238 has a shorter proteasome dis-
sociation half-life and improved antitumor 
activity in human cancer xenograft models and 
a lower incidence and severity of peripheral 
neuropathy [30, 31]. Recently, continuous ad- 
ministration of low-dose cytotoxic agents with-
out extended intervals, also known as “low-
dose chemotherapy”, has been considered as 
an attractive option in colorectal cancer treat-
ment due to its significant reduction in toxic 
side effects and the risk of multidrug resis-
tance development in tumor cells [32].
Given its favorable toxicity profile observed in 
clinical trials, MLN9708 is an attractive thera-
peutic agent to evaluate in human colon can-
cer. To the best of our knowledge, this is the 
first preclinical evaluation of its hydrolyzed 
form, MLN2238, in colon cancer.
Our data show that colon cancer cell death is 
about 10%-15% at 24 h in the different colon 
cancer cell lines, when treated with MLN2238 
alone. However, there was a significant increase 
in death rate (up to 50-65%) when MLN2238 
was combined with BH3 mimetic ABT-737. 
Colony assay data also show that combination 
of MLN2238 and ABT-737 inhibit the colony for-
mation in colon cancer cell lines (Figure S3). 
Recent evidence indicates that anticancer 
drugs can trigger apoptosis and/or autophagy, 
both of which are regulated by the Bcl-2 protein 
family [6, 33]. The Bcl-2 family proteins that 
regulate apoptotic cell death mediate drug-sen-
sitivity in various cancers [34], and they inhibit 
apoptosis by binding to Bax or Bak. Bcl-2 and 
Bcl-xL are also well known for their anti-autoph-
agy abilities [35]. BH3 domain peptide compet-
ed for binding to different antiapoptotic pro-
teins Bcl-xL [36] and led to Noxa selectively 
binding to Mcl-1.
In this study, we explored the effect of MLN2238 
combined with or without BH3 mimetic ABT-
737 upon apoptosis and autophagy, as well as 
Bcl-2 family protein expression levels, in human 
colon cancer cell lines. We found a significant 
upregulation of Mcl-1 in colon cancer cell lines 
treated with MLN2238 alone. This result is 
similar to previous studies about proteasome 
inhibitors which showed that Bortezomib upreg-
ulated Mcl-1 expression in melanoma and 
breast cancer [37, 38]. We reported that MLN- 
2238 induced autophagy as evidenced by con-
version of the autophagosomal marker LC3 
from LC3I to LC3II. In our colon cancer cell 
lines, HCT116 and LOVO, the combination of 
BH3 mimetic and MLN2238 potently downreg-
ulated Mcl-1 but not Bcl-2/Bcl-xl proteins, 
increased PARP cleavage and reduced LC3 II 
expression. We proved that inhibiting Mcl-1 
expression enhances MLN2238 induced apop-
tosis and negatively regulates autophagy. 
Autophagy is an evolutionarily conserved cata-
bolic pathway that targets cellular organelles 
and cytoplasmic constituents to the lysosomes 
for degradation and has multiple roles in carci-
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nogenesis and cancer therapy [12]. Autophagy 
may serve as a cell survival mechanism that 
occurs in response to cellular stress induced by 
nutrient deprivation or chemotherapy. However, 
the molecular mechanisms that govern the 
interplay between autophagy and apoptosis 
are poorly understood. Apoptosis induced cell 
death accounted for 20% in programmed cell 
death. It is likely that mitochondrial related 
autophagy blocked mitochondria dependent 
apoptotic pathway to delay apoptosis [39, 40]. 
The finding that MLN2238 induced both apop-
tosis and autophagy may be related to its ability 
to trigger endoplasmic reticulum (ER) stress. 
BH3 mimetic induces autophagy via blockage 
of the Bcl-2-Beclin-1 interaction at the endo-
plasmic reticulum [41]. Since both MLN2238 
and ABT-737 can induce autophagy to antago-
nize the apoptotic effect, we hypothesized in- 
creased autophagy would occur when these 
two drugs were combined. In fact, we found 
decreased expression of Mcl-1 and LC3II in the 
combination treatment group in HCT116 and 
LOVO cells, which is different from our hypoth-
esis, but not in SW480, RKO or HT-29 cell lines. 
Immunoblots of cleaved PARP corroborate the 
fact that the combination treatment induced 
apoptosis synergistically in cell line in HCT116 
and LOVO, but not in SW480 and HT-29. We 
attempted to determine whether the expres-
sion of other anti-apoptotic Bcl-2 family mem-
bers would change after combination therapy. 
We found Bcl-2 and Bcl-xl expression did not 
change in any of the colon cancer cell lines, 
while Beclin-1 decreased in HCT116 and LOVO 
cells but not in SW480 or HT-29 cells. When we 
compared the result with genomic features of 
these colon cancer cell lines [42], we found 
those with WT P53 benefit the most from the 
combination treatment, and cell lines with P53 
mutations were resistant to the combination of 
drugs. To confirm efficacy of combination thera-
py in colon cancer cell lines correlated with P53 
status, we performed the treatment as indicat-
ed previously using the HCT116 P53-/- and nor-
mal HCT116 cell lines. We found the HCT116 
P53-/- cell line was resistant to the combina-
tion of MLN2238 plus ABT-737 and showed 
increased Mcl-1 and LC3II expression as com-
pared to control HCT116 cells. Immunoblot 
analyses also demonstrated that MLN2238 
plus ABT-737 decreased ERK phosphorylation 
in HCT116 cells but not in the HCT116 P53-/- 
cell line (Figure S2). Our result is consistent 
with a previous finding that blocking LC3 lipida-
tion or ATG5-ATG12 conjugation decreases 
ERK phosphorylation, independent of changes 
in MEK phosphorylation [43]. It has been 
reported that transcriptional regulation of Mcl-1 
by Sp1 is repressed by p53 [44]. Transcriptional 
activity of STAT3 and HIF-1a which activate 
transcription of Mcl-1, is also inhibited by p53 
[45, 46]. Together, P53 status can be used as 
an indicator for predicting sensitivity of this 
combination treatment. Interestingly, RKO cell 
lines with WT P53 did not show a significant 
reduction of LC3I to LC3II conversion (Figure 
S1), but we still found decreased Mcl-1 and 
increased cleavage of PARP after the combina-
tion treatment. The reason why the RKO cell 
line is different from other WT P53 colon can-
cer cell lines may be because RKO cells pos-
sess the BRAF V600E mutation, and tumor 
cells with BRAF V600E mutations display high 
rates of induced autophagy [47]. Together, 
these data indicate that autophagy is serving a 
prosurvival function in MLN2238 treated colon 
cancer cells. Consistent with these results, we 
demonstrated that co-administration of ABT-
737 enhances the anti-cancer effects of MLN- 
2238 through decreased Mcl-1 expression and 
autophagy inhibition. 
MLN9708 is a boronic acid analogue that selec-
tively and reversibly inhibits the b5 subunit 
sites of the 20S proteasome. Structurally, 
MLN9708 (ixazomib citrate) is an orally admin-
istered drug that is hydrolyzed into its active 
form, MLN2238 (ixazomib). Compared with 
Bortezomib, data from clinical trials show that 
MLN9708 has a lower incidence of peripheral 
neuropathy [48, 49]. This makes MLN9708 
potentially more suitable for using in combina-
tion therapy regimens in human colorectal 
cancer.
In summary, our findings demonstrate that 
MLN2238 can induce both apoptosis and au- 
tophagy in human colorectal cancer cell lines, 
with increased Mcl-1 expression. ABT-737 was 
shown to potentiate MLN2238 mediated apop-
tosis by inhibiting autophagy, resulting in a syn-
ergistic cytotoxic effect. Furthermore, this syn-
ergistic effect correlates with P53 status. 
Inhibition of autophagy by MLN2238 plus ABT-
737 was shown to drive more colon cancer 
cells into apoptosis and induce more cell death, 
indicating that autophagy serves a prosurvival 
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role in these colon cancer cells subjected to 
cellular stress. Our in vivo data proved combi-
nation of MLN2238 and ABT-737 produced 
greater inhibition of tumor growth. Together, 
our data provide in vitro and in vivo evidence 
that MLN9708 plus ABT-737 has the potential 
to be a new therapeutic strategy for the treat-
ment of human colorectal cancer.
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Supplementary method
Colony formation
Colony formation in HCT116, LOVO, SW480, HT-29 clones on culture plates. Each bar represents the 
average number of colonies formed by the different cell lines. For analyses of colony formation on cul-
ture plates, 1.0 times 103 cells were plated into each well of a six-well plate and exposed previously to 
DMSO (Ctrl), MLN2238, and/or ABT-737 for 24 h. Cell lines were treated with MLN2238 (200 nM) and/
or ABT-737 (2 μM). These cells allowed to grow for 14-20 days. Colonies of cells were stained with 0.1% 
crystal violet and the total number of colonies per well were counted using Colony 1.1 software (Fujifilm, 
Tokyo, Japan).
Supplementary Figure 1. ABT-737 sensitizes RKO cells to MLN2238. Cultured RKO cells were treated with doses of 
MLN2238 (200 nM), ABT737 (2 μM), or the combination for 24 h. A. Flow cytometry analysis of annexin-V and prop-
idium iodide (PI) staining of apoptotic cells following the treatment. B. Protein lysates were harvested and western 
blots performed using antibodies for Mcl-1, LC3, Beclin1, Atg5, Bcl-xL, Bcl2, PARP and Actin. C. The CI was calculat-
ed after treatment of MLN2238 and ABT-737 at a fixed ratio (1:10). Isobologram showing CI < 1 indicates synergy. 
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Supplementary Figure 2. Combination induced p-ERK expression decrease is P53 related. Cultured HCT116 and 
HCT116 P53-/- cells were treated with doses of MLN2238 (200 nM), ABT737 (2 μM), or the combination for 24 h. 
Protein lysates were harvested and western blots performed using antibodies for p-ERK and T-ERK.
Supplementary Figure 3. ABT-737 sensitizes cells to MLN2238. Cell lines were treated with doses of MLN2238 
(200 nM), ABT737 (2 μM), or the combination for 24 h. Colonies of cells were counted after 14-20 days. Mean ± SD. 
*, P < 0.05, **, P < 0.005, relative to Control.
